Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011; Massachusetts Medical Society; Volume: 365; Issue: 10 Linguagem: Inglês
10.1056/nejmoa1009638
ISSN1533-4406
AutoresManesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E. Singer, Werner Hacke, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Jonathan P. Piccini, Richard C. Becker, Christopher C. Nessel, John F. Paolini, Scott D. Berkowitz, Keith A.A. Fox, Robert M. Califf,
Tópico(s)Cardiac Arrhythmias and Treatments
ResumoThe use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
Referência(s)